HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 54.9%

Neg 54.9% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $26.